However, distant failure remains a burden for patients with unresectable NSCLC: Over time 30% of affected patients develop brain metastases (BM) [9], but there is encouraging evidence that anti-PD-1/PD-L1 agents may have a beneficial impact on their development [10]. Here, CD274 is linked to non-small cell lung carcinoma.